ÂÜÀòÂÒÂ×

Jeff Bird is a seasoned investment professional and managing director at Bluebird Ventures since August 2019. With a long-standing role at Sutter Hill Ventures starting in June 2002, Jeff serves as a limited partner and managing director. In addition to these positions, Jeff holds board membership at Stanford Health Care and is an investor in several therapeutics and diagnostic companies, including Leyden Labs, Foresight Dx, Kriya Therapeutics, Nutcracker Therapeutics, Epirium, and Procyrion, Inc. Jeff also invests in GRAIL, Inc., having been involved since January 2016. Educationally, Jeff earned an MD and a Ph.D. in Cancer Biology from Stanford University School of Medicine between 1982 and 1988, following a Bachelor of Science degree from Stanford University from 1978 to 1982.